| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX001 (ip) | median survival time | saline | 250.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 500.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 500.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 1000.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 1000.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2000.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2000.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | other | 40.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | other | 80.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | other | 160.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | other | 320.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | other | 640.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 150.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 5; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 150.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 5; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 200.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 5; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 200.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 5; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 250.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 5; 04/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 250.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 5; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | alkali diluted with saline | 300.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 5; 04/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | other | 40.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | other | 80.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | other | 160.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | other | 320.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | other | 640.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline | 50.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 100.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 100.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 100.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 200.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 200.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 200.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 400.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 400.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 400.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | other | 20.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 20.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 40.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 40.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 80.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 80.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 160.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | other | 160.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 20.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 25.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 40.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 50.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 80.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 100.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 160.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 45; 05/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with saline | 200.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 00/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with water | 25.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with water | 50.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with water | 100.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | alkali diluted with water | 200.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 25.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 50.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 100.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 200.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 400.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 20.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 40.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 80.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | other | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 9.38 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 18.8 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 20.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 37.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 40.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 40.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 40.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 50.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 50.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 60.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 60.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 5; 09/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 75.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 80.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 150.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with saline | 160.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | alkali diluted with water | 20.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with water | 40.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with water | 80.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with water | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | alkali diluted with water | 320.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 37.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 75.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 150.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 300.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | Klucel (hydroxypropylcellulose) (HPC) | 600.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | other | 20.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | other | 40.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | other | 80.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | other | 160.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | other | 320.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | alkali diluted with saline | 28.13 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 07/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | alkali diluted with saline | 56.25 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | alkali diluted with saline | 112.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | alkali diluted with saline | 225.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | alkali diluted with saline | 450.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/08 animals surviving on day 5 |
| Q04DX003 (iv) | median survival time | other | 20.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (iv) | median survival time | other | 40.0 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (iv) | median survival time | other | 80.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (iv) | median survival time | other | 160.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (iv) | median survival time | other | 320.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |